Janssen Pharmaceutica
Belgian pharmaceutical company founded by Paul Janssen and integrated into Johnson & Johnson’s global innovative-medicines business.
Last updated November 4, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
Janssen Pharmaceutica is a Belgian pharmaceutical company headquartered in Beerse, in the province of Antwerp. Founded in 1953 by physician and pharmacologist Paul Janssen, it developed from a family pharmaceutical distribution and manufacturing business into one of the principal research and development organizations within Johnson & Johnson. The company is associated with the Janssen name used across Johnson & Johnson’s pharmaceutical operations, although the wider business has also operated through entities such as Janssen Research & Development, Janssen Biotech, Janssen Vaccines and Janssen-Cilag. Johnson & Johnson announced a broader identity for its pharmaceutical business as Johnson & Johnson Innovative Medicine in 2023, while Janssen remains an important historical and operating identity. The company’s roots extend to 1933, when Paul Janssen’s father, Constant Janssen, established a Belgian business distributing products of the Hungarian pharmaceutical company Richter. Paul Janssen created an independent research laboratory within that family enterprise in 1953. The laboratory’s early work produced Neomeritine, an antispasmodic introduced in the mid-1950s, and helped establish research-led drug discovery as the company’s defining capability. The corporate name became Laboratoria Pharmaceutica C. Janssen in 1956, and a dedicated research facility opened in Beerse in 1957. The company was acquired by Johnson & Johnson in 1961 and formally became Janssen Pharmaceutica in 1964. Janssen’s portfolio has covered psychiatric and neurological medicines, pain management, infectious diseases, gastrointestinal disorders, dermatology, oncology, immunology, anesthesia and cardiovascular care. Historically associated products include Haldol, Risperdal, Daktarin, Nizoral, Vermox, Imodium, Motilium and Duragesic. Through Johnson & Johnson’s acquisitions and operating structure, the Janssen organization also became associated with biologic medicines such as Remicade, Simponi and Stelara, tuberculosis treatment Sirturo, and the psychiatric medicine Spravato. Product ownership, marketing rights and geographic availability have changed over time, so the Janssen name does not necessarily indicate that every historical product remains marketed by the Belgian company. Research and manufacturing are central to the Beerse-area operation. Janssen established a substantial research campus, later including the Janssen Research Foundation, discovery and drug-safety facilities, pharmaceutical development functions and administrative operations. Its Geel site manufactures active pharmaceutical ingredients and became the main Belgian chemical-production location after production was progressively transferred from Beerse. The company also maintained Belgian activities in Berchem and Olen. Internationally, Janssen’s research and commercial network expanded through Johnson & Johnson’s pharmaceutical subsidiaries and acquisitions, including Centocor, Crucell, Actelion and other businesses. Janssen has also been notable for its early engagement with China. Following discussions between Paul Janssen and physician Ma Haide, the company cooperated with Chinese partners to modernize pharmaceutical production. Xian-Janssen Pharmaceuticals opened a major facility in Xi’an in 1985, making Janssen one of the earliest Western pharmaceutical companies to establish pharmaceutical manufacturing operations in the People’s Republic of China. The company’s history includes significant regulatory and legal controversies. Johnson & Johnson and Janssen faced U.S. allegations concerning the promotion of Risperdal for uses not approved by regulators and alleged payments connected with nursing-home prescribing. In addition, Janssen was involved in opioid-related litigation, including proceedings brought by the State of New York; Johnson & Johnson reached a settlement with New York in 2021. These matters are part of the broader legal history of Johnson & Johnson’s pharmac…
History
Janssen Pharmaceutica grew out of Constant Janssen’s 1933 Belgian distribution business, which represented Richter products in Belgium, the Netherlands and the Belgian Congo. The family company expanded in Turnhout, and Paul Janssen became involved while studying medicine and pharmacology. In 1953 he established a research laboratory within the family operation. His team developed Neomeritine, an antispasmodic, in 1955, providing an early demonstration of the company’s research-based model. The business was renamed Laboratoria Pharmaceutica C. Janssen in 1956. A new research facility opened in Beerse in 1957, and the research department became a separate legal entity in 1958. Johnson & Johnson acquired the company in 1961. In 1964 it adopted the Janssen Pharmaceutica name and moved its legal seat to Beerse. Pharmaceutical production followed the research and administrative functions from Turnhout to Beerse during 1971 and 1972. The Beerse campus became the center of Janssen’s scientific identity. The Janssen Research Foundation was created in 1987, and later organizations integrated Belgian research with Johnson & Johnson’s international development capabilities. In 1999, clinical research and non-clinical development became part of a global Johnson & Johnson structure. Research activities from the Janssen Research Foundation and the U.S.-based R.W. Johnson Pharmaceutical Research Institute were subsequently combined within Johnson & Johnson Pharmaceutical Research and Development, later known as Janssen Research and Development. Janssen expanded its Belgian industrial base through chemical-production facilities in Geel. Plants opened in stages from 1975 through 1995, and remaining chemical production in Beerse was transferred to Geel in 1999. The Beerse site also added pharmaceutical-development, discovery-research, drug-safety, logistics and information facilities during the 2000s. The Paul Janssen Research Center was inaugurated in 2004. Johnson & Johnson broadened the Janssen network through acquisitions and internal rebranding. Centocor became Janssen Biotech in 2011, while the acquisition of Crucell in the same year added vaccine capabilities; Crucell was later known as Janssen Vaccines. Other associated businesses included Cilag, Actelion and Tibotec. Janssen also entered biologics and immunology through Centocor products, including Remicade and Simponi, and pursued collaborations and licensing arrangements with biotechnology companies. The company’s international development included an important China initiative. After Paul Janssen’s discussions with Ma Haide, Janssen worked with Chinese partners to modernize production in Shaanxi. Xian-Janssen Pharmaceuticals opened a factory in Xi’an in 1985, establishing a long-term manufacturing and commercial presence in China. Janssen’s legacy includes medicines listed by the World Health Organization among essential medicines, including haloperidol, miconazole, mebendazole, risperidone and bedaquiline. At the same time, the company and its parent faced serious legal scrutiny. The Risperdal matter involved allegations of improper promotion and payments related to unapproved use in elderly patients, culminating in a multistate U.S. resolution. Opioid litigation later included Janssen as a defendant, with Johnson & Johnson settling with New York State in 2021. The Janssen name has increasingly been incorporated into Johnson & Johnson’s unified pharmaceutical organization. In 2023 Johnson & Johnson adopted Johnson & Johnson Innovative Medicine for the pharmaceutical business, but Janssen Pharmaceutica remains the historical Belgian company and a significant part of the organization’s research, manufacturing and scientific heritage.
- 2023
Johnson & Johnson Innovative Medicine identity introduced
[4]Johnson & Johnson began transitioning its pharmaceutical business to the Johnson & Johnson Innovative Medicine name.
- 2019
FDA approves Spravato
[3]The FDA approved esketamine nasal spray for treatment-resistant major depressive disorder.
- 2011
Centocor becomes Janssen Biotech
[1]Johnson & Johnson renamed Centocor Ortho Biotech as Janssen Biotech as part of a global Janssen identity.
- 2011
Crucell joins Johnson & Johnson’s Janssen network
[1]Johnson & Johnson acquired Crucell and assigned it to Janssen, adding vaccine capabilities.
- 2004
Paul Janssen Research Center inaugurated
[1]The Beerse discovery-research center was formally opened.
- 1998
Remicade reaches the U.S. market
[1]Centocor, later part of the Janssen organization, launched Remicade for Crohn’s disease, with later indications expanding across inflammatory disorders.
- 1987
Janssen Research Foundation founded
[1]The foundation was created to organize discovery research in Beerse and other laboratories.
- 1985
Xian-Janssen factory opens in China
[1]A major pharmaceutical factory opened in Xi’an following cooperation to modernize pharmaceutical production in Shaanxi.
- 1975
Geel chemical production begins
[1]The first Geel chemical-production plant was established, creating the foundation for a major active-ingredient manufacturing complex.
- 1964
Company adopts Janssen Pharmaceutica name
[1]The company changed its name to Janssen Pharmaceutica N.V. and moved its corporate seat to Beerse.
Products and positioning
Research-driven pharmaceutical company focused on innovative prescription medicines, biologics, vaccines and specialty-care therapies.
Antipsychotic · 1994
Risperdal
Risperdal is the historical Janssen brand for risperidone, an atypical antipsychotic developed for psychiatric disorders including schizophrenia and related conditions. It became one of the company’s best-known medicines, while its promotion and marketing practices later became the subject of major U.S. investigations and settlements.
Antipsychotic
Haldol
Haldol is the brand name for haloperidol, a first-generation antipsychotic associated with the treatment of psychotic disorders and severe agitation. It is among the original Janssen medicines included on the WHO Model List of Essential Medicines.
Antifungal
Daktarin
Daktarin is a topical antifungal brand based on miconazole. It has been used for a range of fungal skin and mucosal infections and is one of the long-standing consumer-recognized Janssen brands in several markets.
Anthelmintic
Vermox
Vermox is a mebendazole brand used against intestinal worm infections. Mebendazole is one of the medicines historically developed or commercialized through the Janssen portfolio and is included on the WHO Model List of Essential Medicines.
Pain management · 1990
Duragesic
Duragesic is a transdermal fentanyl delivery system developed for management of persistent severe pain. Because fentanyl is a potent opioid, the product has been subject to extensive prescribing, safety, regulatory and litigation scrutiny.
Biologic immunology medicine · 1998
Remicade
Remicade is infliximab, a monoclonal antibody associated with the Centocor business that became part of Johnson & Johnson’s Janssen organization. Its indications expanded from Crohn’s disease to several inflammatory conditions, including rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, ulcerative colitis and plaque psoriasis.
Anti-tuberculosis medicine · 2012
Sirturo
Sirturo is bedaquiline, a diarylquinoline medicine for multidrug-resistant tuberculosis. Discovered by a Janssen research team, it represented the company’s contribution to developing newer treatments for difficult-to-treat tuberculosis.
Psychiatric medicine · 2019
Spravato
Spravato is an esketamine nasal spray developed for treatment-resistant depression under controlled clinical and distribution arrangements. Its 2019 U.S. approval made it one of the first major antidepressant innovations in decades to use a substantially different pharmacological approach.
Gastrointestinal medicine
Imodium
Imodium is the loperamide brand associated with treatment of diarrhea. It is one of the historical Janssen products and has been sold in various markets through different Johnson & Johnson or local commercial arrangements.
Antifungal
Nizoral
Nizoral is a ketoconazole brand historically used for fungal infections and dandruff. The brand illustrates Janssen’s earlier strength in anti-infective and dermatology products, although formulations, indications and ownership have changed across markets.
Controversies
2021
Opioid litigation involving Janssen
Janssen was named in opioid litigation brought by New York Attorney General Letitia James. Johnson & Johnson agreed to a settlement with New York State, after which Janssen was removed from the case.
2019
Encinitas sues opioid manufacturers and distributors
The city of Encinitas filed a lawsuit against multiple companies and parties in the opioid industry, alleging that manufacturers and distributors engaged in conduct that led doctors to prescribe opioids and neglected to warn consumers about their addictiveness. The suit named Teva Pharmaceutical Industries USA Inc., Janssen Pharmaceuticals Inc., AmerisourceBergen Corp. and Purdue Pharma's owners, the Sackler family.
2012
Risperdal marketing and kickback case
The U.S. Department of Justice and state authorities pursued allegations that Johnson & Johnson and Janssen promoted Risperdal for unapproved uses, including use in elderly patients, and provided improper payments or incentives connected with nursing-home prescribing. The case resulted in a multistate resolution and criminal and civil penalties.
Marketing campaigns
- 2017Pandemic influenza vaccine collaboration
United States · Global research network
Janssen collaborated with BARDA on pandemic influenza vaccine research, including work toward a vaccine capable of protecting against a broad range of influenza strains.
Outcome. Expanded Janssen’s public-health and vaccine-development role.
- 2007Innerstate
United States
Centocor released a theatrically distributed documentary-style film connected with Remicade. The project was notable because it was presented as a patient-centered film funded and created by a pharmaceutical company to discuss life with inflammatory disease.
Outcome. Raised awareness of patient experience and became an early example of long-form branded pharmaceutical storytelling.
Brand decisions
2023
Transition pharmaceutical business identity to Johnson & Johnson Innovative MedicineStrategyBackground
Johnson & Johnson sought a clearer corporate identity for its pharmaceutical business after separating its consumer-health activities into Kenvue.
Action taken
The corporation introduced Johnson & Johnson Innovative Medicine as the principal identity for the pharmaceutical segment.
Aftermath
Janssen Pharmaceutica remained an important historical and operating entity, while the broader Janssen brand became less central to corporate presentation.
2020
Accelerate COVID-19 vaccine developmentProduct launchBackground
The COVID-19 pandemic created an urgent need for vaccines and public-sector support for rapid development and manufacturing.
Action taken
BARDA allocated funding to Johnson & Johnson and Janssen for vaccine development and related work.
Aftermath
The program added a major pandemic-response project to Janssen’s vaccine and infectious-disease activities.
BARDA allocation. 456 million USD (2020)
2019
Launch Spravato for treatment-resistant depressionProduct launchBackground
Patients with treatment-resistant depression had limited options and a need for therapies using mechanisms different from conventional oral antidepressants.
Action taken
Janssen obtained U.S. FDA approval for esketamine nasal spray, with controlled administration requirements.
Aftermath
Spravato became a major psychiatric launch and broadened Janssen’s modern neuroscience portfolio.
2011
Unify Johnson & Johnson pharmaceutical businesses under JanssenStrategyBackground
Johnson & Johnson operated pharmaceutical businesses under several historical names, including Centocor and Ortho Biotech.
Action taken
Centocor Ortho Biotech was renamed Janssen Biotech as part of a global effort to create a more consistent Janssen identity.
Aftermath
The Janssen name became more prominent across biologics and specialty medicines within Johnson & Johnson.
1961
Join Johnson & JohnsonM&ABackground
Janssen had developed a research-led Belgian pharmaceutical model but needed the scale and international infrastructure of a larger pharmaceutical group.
Action taken
The company was sold to Johnson & Johnson and operated as part of its pharmaceutical organization.
Aftermath
The transaction enabled international expansion while preserving Beerse as a major research and manufacturing center.
Recent events
Bayer and Janssen sue Micro Labs over Xarelto patents[6]
Reported:
Bayer Pharma AG, Bayer AG, and Janssen Pharmaceuticals Inc. filed a patent-infringement case against Micro Labs LTD and Micro Labs USA Inc. concerning Xarelto. The plaintiffs seek declaratory and injunctive relief and expenses.
Midatech and Janssen extend Q-Sphera research collaboration[7]
Midatech announced that it had extended its research and development collaboration with Janssen. The extended work will focus on maximizing drug loading and optimizing in vitro duration of release for an undisclosed Janssen experimental molecule using Q-Sphera technology.
SRI International and Janssen announce collaboration[8]
Reported:
SRI International announced a collaboration agreement with Janssen to use SRI’s SynFini platform for small-molecule drug discovery and further platform development.
Janssen agrees to supply COVID-19 vaccine doses to African Union members[9]
Reported:
Janssen Pharmaceutica N.V. signed an agreement with the African Vaccine Acquisition Trust to provide up to 220 million doses of its single-shot COVID-19 vaccine candidate to the African Union’s 55 member states starting in the third quarter of 2021. Supply depends on national regulatory approval or authorization.
Morphic and Janssen expand research collaboration to a third integrin target[10]
Reported:
Morphic announced an expansion of its research and development collaboration with Janssen, initiating work on a third integrin target and including activating antibodies against that target.
Janssen acquires rights to HMR59 gene therapy[11]
Reported:
Janssen Pharmaceuticals acquired from Hemera Biosciences the rights to HMR59, an investigational one-time intravitreal injection gene therapy being developed for geographic atrophy.
Exonate and Janssen announce retinal disease treatment collaboration[12]
Reported:
Exonate announced a collaboration with Janssen Pharmaceuticals to develop eye drops for retinal vascular diseases, using mRNA-targeted therapies. The collaboration agreement was facilitated by Johnson & Johnson Innovation.
Janssen completes acquisition of bermekimab rights[13]
The Janssen Pharmaceutical Companies of Johnson & Johnson completed the acquisition from XBiotech of all rights to investigational bermekimab, along with certain employees, for $750 million.
Encinitas sues opioid manufacturers and distributors[5]
Reported:
The city of Encinitas filed a lawsuit against multiple companies and parties in the opioid industry, alleging that manufacturers and distributors engaged in conduct that led doctors to prescribe opioids and neglected to warn consumers about their addictiveness. The suit named Teva Pharmaceutical Industries USA Inc., Janssen Pharmaceuticals Inc., AmerisourceBergen Corp. and Purdue Pharma's owners, the Sackler family.
Sources14 sources
- 1Janssen Pharmaceuticalsen.wikipedia.org
- 2Johnson & Johnson pays more than $2 billion to resolve criminal and civil investigationsjustice.gov
- 3FDA approves new nasal spray medication for treatment-resistant depressionfda.gov
- 4Johnson & Johnson announces Kenvue spin-off completion and new company namejnj.com
- 5Encinitas sues opioid manufacturers and distributorstimesofsandiego.com
- 6Encinitas sues opioid manufacturers and distributorslawstreetmedia.com
- 7Midatech 与 Janssen 延长 Q-Sphera 研究合作stlouisstar.com
- 8SRI International与Janssen宣布合作prnewswire.com
- 9杨森制药同意向非洲联盟成员国供应新冠候选疫苗prnasia.com
- 10Morphic 与 Janssen 将研究合作扩展至第三个整合素靶点finance.yahoo.com
- 11Janssen获得HMR59基因疗法权利healio.com
- 12Exonate与杨森宣布合作开发视网膜疾病疗法healio.com
- 13Janssen完成对bermekimab权利的收购biospectrumindia.com
- 14Janssen acquires rights to Hemera’s eye-disorder gene therapypharmaceutical-business-review.com
Cite this profile: Cite the canonical profile. /brand-wiki/janssen-pharmaceutica · Editorial policy · How profiles are compiled